

L J J Derijks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5285952/publications.pdf>

Version: 2024-02-01

8
papers

344
citations

1306789

7
h-index

1588620

8
g-index

8
all docs

8
docs citations

8
times ranked

569
citing authors

#	ARTICLE	IF	CITATIONS
1	Review article: thiopurines in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 715-729.	1.9	149
2	Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 356-363.	1.9	61
3	Safety of thiopurines in the treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 69-72.	0.6	43
4	Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal <i>TPMT</i> genotype. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 953-963.	1.9	31
5	Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease and Established Azathioprine Therapy. <i>Clinical Drug Investigation</i> , 2004, 24, 479-486.	1.1	29
6	Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. <i>Clinical Rheumatology</i> , 2017, 36, 2129-2134.	1.0	17
7	The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine. <i>Pharmacogenomics Journal</i> , 2018, 18, 160-166.	0.9	9
8	A value proposition for trough level-based anti-TNF α drug dosing. <i>Clinica Chimica Acta</i> , 2019, 489, 89-95.	0.5	5